Pharmacological analysis of the effects of the neuropeptide Y antagonist BMS 193885 on the emotional, intraspecies behavior and reinforcing properties of ethanol in rats

Cover Page


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Purpose. Our previously data on orexigenic peptides (orexin, ghrelin) showed antagonists of peptides receptors as correctors of the emotional-motivational and cognitive spheres. Currently, a close relationship between ghrelin and orexin with neuropetide Y has been shown in feeding and emotional behavior.

The aim of this work was to analyze the effect of the NPY antagonist Y1R BMS 193885 on emotional and intraspecies behavior, as well as on the reinforcing properties of ethanol in rats.

Methods. We used the “open field” test, “elevated plus-maze”, Porsolt’s forced swimming test, “resident – intruder” test, conditional place preference (CPP). BMS 193885 1 mg/ml, 20 μl intranasally did not cause an anxiogenic effect in the “elevated plus-maze”.

Results. In the Porsolt’s test, there was also no increase in the level of depression. Moreover, there was a significant decrease in the number and time of dives, as an indirect indicator of a decrease in the level of depression. At the same time, in the “resident – intruder” test were decreased protective behavior, as an indicator of a decrease in the stress of intraspecific interaction in the absence of aggression. Moreover, local movements were increased in the “open field” test as an indicator of the animal’s activity impaired by fear. BMS 193885 had no effect on the expression of the CPP of ethanol.

Conclusion. Thus, it was previously shown that the BMS 193885 is a powerful, selective, brain-penetrating Y1 receptor antagonist, it reduces food intake and body weight in animal models of obesity both after acute and chronic administration. Our data indicate that the decrease in food intake is not associated with the level of anxiety, depression, or with a change in intraspecific interaction. It has been previously shown that NPY reduces alcohol consumption. Our data indicate that the Y1R antagonist of the neuropeptide Y BMS 193885 does not cause a change in the CPP of alcohol.

Full Text

Restricted Access

About the authors

Aleksander R. Moskalyev

Institute of Experimental Medicine

Author for correspondence.
Email: dr.moskalev91@gmail.com

Post-graduate Student, Dept. of Neuropharmacology

Russian Federation, Saint Petersburg

Maxim E. Abrosimov

Institute of Experimental Medicine

Email: abrosimovmaxim1990@mail.ru

Post-graduate student, Dept. of Neuropharmacology

Russian Federation, Saint Petersburg

Eduard A. Vetlugin

Institute of Experimental Medicine

Email: vetedd@yandex.ru

Post-graduate student, Dept. of Neuropharmacology

Russian Federation, Saint Petersburg

Anna G. Pshenichnaya

Institute of Experimental Medicine

Email: bychkov@mail.ru

Senior Engineer, Dept. of Neuropharmacology

Russian Federation, Saint Petersburg

Ilya Yu. Tissen

Institute of Experimental Medicine

Email: ilja_tis@mail.ru

PhD (Pharmacology), Senior Researcher, Dept. of Neuropharmacology

Russian Federation, Saint Petersburg

Anatoliy S. Ivankov

Institute of Experimental Medicine

Email: ilja_tis@mail.ru

Post-graduate Student, Dept. of Neuropharmacology

Russian Federation, Saint Petersburg

Eugenii R. Bychkov

Institute of Experimental Medicine

Email: bychkov@mail.ru

PhD (Pathophysiology), Head of the Laboratory of Chemistry and Pharmacology of Medicinal Compounds, Dept. of Neuropharmacology

Russian Federation, Saint Petersburg

Andrei A. Lebedev

Institute of Experimental Medicine

Email: aalebedev-iem@rambler.ru

Dr. Biol. Sci. (Pharmacology), Head of the Laboratory of General Pharmacology, Dept. of Neuropharmacology

Russian Federation, Saint Petersburg

Petr D. Shabanov

Institute of Experimental Medicine

Email: pdshabanov@mail.ru

Dr. Med. Sci. (Pharmacology), Professor and Head, Dept. of Neuropharmacology

Russian Federation, Saint Petersburg

References

  1. Айрапетов М.И., Сексте Э.А., Ереско С.О., и др. Хроническая алкоголизация приводит к изменению уровня мРНК рецептора орексина первого типа (OX1R) в эмоциогенных структурах мозга крыс // Биомедицинская химия. – 2018. – Т. 64. – № 5. – С. 451–454. [Airapetov MI, Sekste EA, Eresko SO, et al. Chronic alcoholism influences the mRNA level of the orexin receptor type 1 (OX1R) in emotiogenic structures of the rat brain. Biomed. khimiya. 2018;64(5):451-454. (In Russ.)]. https://doi.org/ 10.18097/PBMC20186405451.
  2. Карпова И.В., Бычков Е.Р., Лебедев А.А., Шабанов П.Д. Блокада орексиновых рецепторов ядра ложа конечной полоски повышает уровень серотонина только в левом гипоталамусе // Обзоры по клинической фармакологии и лекарственной терапии. – 2018. – Т. 16. – № 2. – С. 33–36. [Karpova IV, Bychkov ER, Lebedev AA, Shabanov PD. Blockade of orexin receptors in the bed nucleus of stria terminalis increases serotonin level only in the left hypothalamus. Reviews on clinical pharmacology and drug therapy. 2018;16(2):33-36. (In Russ.)]. https://doi.org/10.17816/RCF16233-36.
  3. Королева С.В., Ашмарин И.П. Нейропептид Y: многообразие и кажущаяся противоречивость функций. Анализ возможных опосредованных эффектов // Успехи физиологических наук. – 2000. – Т. 31. – № 1. – С. 42–46. [Koroleva SV, Ashmarin IP. Neuropeptide Y: variety and apparent inconsistency of functions. Analysis of possible indirect effects. Uspekhi fiziologicheskikh nauk. 2000;31(1):42-46. (In Russ.)]
  4. Шабанов П.Д., Морозов В.И., Лебедев А.А. Влияние грелина и его антагониста [D-LYS3]-GHRP-6 на условную реакцию предпочтения места этанола у хронически алкоголизированных крыс // Вопросы наркологии. – 2017. – № 7. – С. 22–31. [Shabanov PD, Morozov VI, Lebedev AA. The effects of ghrelin and its antagonist [D-LYS3]-GHRP-6 on the conditioned place preference in chronically alcoholized rats. Voprosy narkologii. 2017;(7):22-31. (In Russ.)]
  5. Шабанов П.Д., Лебедев А.А., Морозов В.И., Роик Р.О. Подкрепляющие свойства психоактивных веществ модулируются системой пептидов орексина головного мозга // Наркология. – 2016. – Т. 15. – № 4. – С. 27–33. [Shabanov PD, Lebedev AA, Morozov VI, Roik RO. The reinforcing properties of psychoactive drugs are modulated by the brain orexin peptides system. Narcology. 2016;15(4):27-33. (In Russ.)]
  6. Шабанов П.Д., Лебедев А.А., Морозов В.И., Азаренко С.В. Возможное взаимодействие рецепторов орексина и опиоидов в структурах расширенной миндалины при оценке подкрепляющих эффектов спонтанной и активированной самостимуляции латерального гипоталамуса // Вопросы наркологии. – 2017. – № 2–3. – С. 155–168. [Shabanov PD, Lebedev AA, Morozov VI, Azarenko SV. A possible interaction of orexin and opioid receptors of the extended amygdala structures in the reinforcing effects of spontaneous and activated self-stimulation of the lateral hypothalamus. Voprosy narkologii. 2017;(2–3):155-168. (In Russ.)]
  7. Antal-Zimanyi I, Bruce MA, Leboulluec KL, et al. Pharmacological characterization and appetite suppressive properties of BMS-193885, a novel and selective neuropeptide Y(1) receptor antagonist. Eur J Pharmacol. 2008; 590(1-3):224-232. https://doi.org/10.1016/j.ejphar. 2008.06.032.
  8. Blomqvist A, Lundell M, Larhammar D. Strong evolutionary conservation of neuropeptide Y between mammals, chicken, goldfish and horned shark. Ann NY Acid Sci. 1990;611(1):378. https://doi.org/10.1111/ j.1749-6632.1990.tb48956.x.
  9. Cippitelli A, Rezvani AH, Robinson JE, et al. The novel, selective, brain-penetrant neuropeptide Y Y2 receptor antagonist, JNJ-31020028, tested in animal models of alcohol consumption, relapse, and anxiety. Alcohol. 2011; 45(6):567-576. https://doi.org/10.1016/j.alcohol.2010. 09.003.
  10. Heilig M. The NPY system in stress, anxiety and depression. Neuropeptides. 2004;38(4):213-224. https://doi.org/10.1016/j.npep.2004.05.002.
  11. Lindner D, Stichel J, Beck-Sickinger AG. Molecular recognition of the NPY hormone family by their receptors. Nutrition. 2008;24(9):907-917. https://doi.org/10.1016/j.nut.2008.06.025.
  12. Michel MC, Beck-Sickinger A, Cox H, et al. XVI. International Union of Pharmacology recommendation for the nomenclature of neuropeptide Y, peptide YY, and pancreatic polypeptide receptors. Pharmacol Rev. 1998;50(1):143-150.
  13. Tatemoto K, Carlquist M, Mutt V. Neuropeptide Y – a novel brain peptide with structural similarities to peptide YY and pancreatic polypeptides. Nature. 1982;269(5858): 659-660. https://doi.org/10.1038/296659a0.
  14. Thorsell A, Slawecki CJ, Ehlers CL. Effects of neuropeptide Y and corticotropin-releasing factor on ethanol intake in Wistar rats: interaction with chronic ethanol exposure. Behav Brain Res. 2005;161(1):133-140. https://doi.org/10.1016/j.bbr.2005.01.016.
  15. Wang C, Han X, Guo F, et al. Orexin-A signaling in the paraventricular nucleus modulates spontaneous firing of glucose-sensitive neurons and promotes food intake via the NPY pathway in rats. Biochem Biophys Res Commun. 2018;505(1):162-167. https://doi.org/10.1016/j.bbrc.2018.09.091.
  16. Xapelli S, Agasse F, Ferreira R, et al. Neuropeptide Y as an endogenous antiepileptic, neuroprotective and pro-neurogenic peptide. Recent Pat CNS Drug Discov. 2006;1(3):315-324. https://doi.org/10.2174/ 157488906778773689.

Copyright (c) 2020 Moskalyev A.R., Abrosimov M.E., Vetlugin E.A., Pshenichnaya A.G., Tissen I.Y., Ivankov A.S., Bychkov E.R., Lebedev A.A., Shabanov P.D.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 65565 от 04.05.2016 г.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies